From PCOS to PMOS: does the rename open the door for Ozempic?

A name a decade in the making

For years, women have walked out of clinics being told they have PCOS when their metabolism is not working fine. That one sentence did a lot of quiet damage. And in May 2026, the medical world finally corrected it: polycystic ovary syndrome, or PCOS, was officially renamed polyendocrine metabolic ovarian syndrome — PMOS — in a global consensus published in The Lancet.

The argument behind it is far older than the headline suggests. The syndrome was first described in 1935 by two doctors, Stein and Leventhal, who noticed a cluster of women with irregular periods, excess hair growth, and ovaries dotted with small follicles. They named it after the one thing they could see — the ovaries — and that label stuck for the better part of a century, even as the science moved past it. By 1990, an NIH panel had decided the condition was really about excess androgens and dropped ovarian appearance from its criteria; then in 2003 the Rotterdam criteria put it back, but only as one of three boxes — irregular periods, high androgens, polycystic-looking ovaries — of which any two were enough to diagnose.

That same moment forced an uncomfortable realisation: there isn't one PCOS, but several. The classic form, with all three features, tends to carry the heaviest metabolic load; at the other end sits a milder version with no excess androgens at all. Different women had quietly been living with different conditions under one label. By 2012, an NIH workshop said out loud what many already felt — that a name fixated on cysts was neither accurate nor helpful. Then, for more than a decade, nothing changed. What did move was the evidence: the first rigorous international evidence-based guidelines for managing the condition were published in 2023. So the 2026 rename isn't a sudden rebrand. It's the close of a ninety-year argument.

And once you see it that way, the old name was a misnomer from the start. The “cysts” on an ultrasound aren't abnormal growths at all — they're eggs that never got released, because the hormonal environment wasn't right for them to mature. The ovary was never the cause. It sat downstream of a much larger story: a cascade of hormones, and a metabolic system under strain.

The new name says that out loud. Polyendocrine points to the many hormones involved, rather than one gland misbehaving. Metabolic puts the way your body handles sugar, fat, and energy at the centre, where it belongs. And ovarian keeps the ovary in the picture as something affected — not as the villain. Getting there took years and tens of thousands of patients and clinicians from around the world, and the conclusion was blunt: the old name had caused real harm — delayed diagnoses, wrong treatments, and a generation of women told their symptoms were “just hormonal.”

Why a name change is really a treatment change

Here's the part that matters beyond semantics: when a condition is named correctly, it tends to get treated correctly. PMOS is now formally recognised as something that reaches well past the ovaries — into insulin resistance (how well your body handles sugar), cardiovascular health, mental health, fertility, and long-term metabolic risk, including type 2 diabetes.

And that is exactly the door semaglutide walks through — the molecule behind Ozempic and Mounjaro. Semaglutide belongs to a class of drugs called GLP-1 receptor agonists, originally built for type 2 diabetes and weight management. Because PMOS is, at its root, a metabolic condition, these drugs have started turning up in the research for it too. The rename didn't create that link. It just made it impossible to ignore.

What semaglutide actually does — and where it starts

To see why, it helps to follow the chain backwards. Most women with PMOS carry some degree of insulin resistance — which simply means your cells don't respond well to insulin. The pancreas compensates by pumping out more of it, and that excess insulin nudges the ovaries into producing more androgens, the male-type hormones like testosterone. That surplus androgen is what eventually shows up as irregular periods, acne, thinning hair, and trouble conceiving. So the symptoms you notice in the mirror usually begin several steps earlier — in how your body is handling sugar.

GLP-1 medicines like semaglutide work near the top of that chain rather than the bottom. They improve how your body responds to insulin, which quietens the downstream hormonal cascade; they support weight loss, which in many women with PMOS is enough on its own to restore ovulation; and they lower inflammation, which is itself a player in hormonal disruption.

The androgen story deserves to be read carefully rather than cheered. A recent meta-analysis found that semaglutide lowered total testosterone compared with a placebo — but that edge disappeared when it was measured against metformin, and free testosterone, the biologically active form, didn't change significantly at all. In plain terms: on androgens alone, semaglutide doesn't clearly beat the metformin we already have.

Where it does seem to pull ahead is in combination. One 2025 trial put semaglutide plus metformin against metformin alone in 100 women with PMOS over sixteen weeks. It was small and short, so it's a signal rather than a verdict — but the combination group saw greater weight loss, better insulin control, and more regular cycles. There's also early work suggesting GLP-1 medicines may act directly on the uterine lining and on ovulation, not only through weight loss. That research is still young, and worth watching rather than treating as settled.

Why this isn't just another weight-loss pill

It's fair to be sceptical, because the world has watched a long line of weight-loss drugs arrive as miracles and leave in disgrace. One was essentially an amphetamine, sold widely until its potential for abuse ended it. Another, in the 1970s, was pulled after it damaged heart valves. A later one looked cleaner, then turned out to raise the risk of heart attacks and strokes. Each suppressed appetite by force. Each eventually failed on safety.

GLP-1 medicines sit in a different place — and that's the point worth holding onto if you've heard all of this before. They don't work by chemically overriding the brain's hunger switch. They work with your body's own metabolic signalling, the same pathway that exercise leans on to bring appetite back in line with what the body actually needs. That's why the metabolic benefits in PMOS are biologically plausible rather than coincidental. It's also why they aren't a free pass: they carry real side effects, and the decision to use one belongs in a conversation with your doctor — not in a trend.

Where India stands right now

Semaglutide cleared India's drug regulator, the CDSCO, in 2025, and Ozempic was formally launched here soon after. But metformin still holds first line for PMOS in India — and rightly so. It's affordable, available everywhere, and backed by decades of safety data. Where it fits at all, semaglutide is an emerging add-on, not a replacement. Women are already asking about it, which is exactly why it's worth understanding properly rather than through a headline.

So who is this actually for?

This is where it's worth being honest, because the answer is: far fewer women than the hype suggests. In practice, the conversation tends to make sense only for women whose PMOS comes with significant metabolic strain, who haven't responded to lifestyle changes and metformin, and who aren't planning a pregnancy soon — because the medicine has to be stopped well before trying to conceive. And for some women it's ruled out entirely: a personal or family history of a specific thyroid cancer, or a condition called MEN2, makes it off-limits.

One line matters above all the rest: semaglutide has no approved use for PMOS anywhere in the world yet. Any use in this setting is off-label. That isn't a reason to fear it — it's the reason this has to be a proper conversation with your doctor about benefits, risks, and the alternatives, rather than something you sort out from a reel.

A clinician's honest caution

The buzz around Ozempic is real. So is the science. But the two are moving at very different speeds. The rename does not mean every woman with PMOS should be on semaglutide. The evidence is promising and still early; the long-term safety data around fertility are thin; we know very little about how it behaves in lean women with PMOS; and its use in teenagers is essentially unstudied. None of that is a reason to dismiss it. It's a reason to walk into the conversation informed — to lead it, rather than be pulled along by it.

This is the kind of thing we go deep on inside Live Gracious — understanding your body, not just managing a diagnosis. If that's the company you want while you figure yours out, join the waitlist.

This article is educational and based on current clinical understanding. It is not a prescription or a substitute for personalised medical advice. Semaglutide is not approved for PMOS/PCOS; any use is off-label. Always talk to your treating doctor before starting, stopping, or changing any medication.